Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 36.43.
Forward PE Ratio (36.43) = Close Price ($237.10) / Consensus Forward EPS ($6.51)
FORWARD PE RATIO
36.43
SECTOR MEDIAN · HEALTHCARE
20.29
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
+79.59%
vs the sector median at left
Alnylam Pharmaceuticals, Inc.
Market Cap
$31.73B
Forward PE Ratio
36.43
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.73B | 36.43 |
| Centene Corp. (CNC)vs › | $31.99B | 13.48 |
| Biogen Inc. (BIIB)vs › | $32.28B | 17.54 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $32.40B | 14.56 |
| Zoetis Inc. (ZTS)vs › | $32.42B | 12.37 |
| Waters Corporation (WAT)vs › | $31.02B | 28.45 |
| Medline Inc. (MDLN)vs › | $29.83B | 23.38 |
| DexCom, Inc. (DXCM)vs › | $34.27B | 34.05 |
| ResMed Inc. (RMD)vs › | $34.86B | 21.60 |
| Alcon Inc. (ALC)vs › | $35.12B | 20.43 |
Trailing P/E
40.0
reported TTM EPS
Forward P/E
36.4
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.51 implies +10.0% EPS growth vs the reported trailing $5.92.
At today's $237.10 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $6.51 | $6.06 – $6.98 | 15 | 36.4x |
| 2027-12-31 | $9.56 | $6.80 – $10.86 | 15 | 24.8x |
| 2028-12-31 | $11.83 | $-2.07 – $17.66 | 17 | 20.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute